Computational Biology
Description
Global Computational Biology Market to Reach US$15.3 Billion by 2032
The global market for Computational Biology estimated at US$6.1 Billion in the year 2025, is expected to reach US$15.3 Billion by 2032, growing at a CAGR of 14.0% over the analysis period 2025-2032. Databases Offering, one of the segments analyzed in the report, is expected to record a 14.1% CAGR and reach US$6.9 Billion by the end of the analysis period. Growth in the Infrastructure & Hardware Offering segment is estimated at 11.9% CAGR over the analysis period.
The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 13.4% CAGR
The Computational Biology market in the U.S. is estimated at US$1.8 Billion in the year 2025. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.7 Billion by the year 2032 trailing a CAGR of 13.4% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.0% and 12.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.5% CAGR.
Global Computational Biology Market - Key Trends and Drivers Summarized
How Is Computational Biology Transforming Research and Innovation in Life Sciences?
Computational biology is revolutionizing the field of life sciences by applying mathematical models, algorithms, and data analysis techniques to biological data, helping researchers unlock complex biological processes that were previously inaccessible. This interdisciplinary field integrates biology, computer science, and mathematics to solve biological problems, ranging from understanding gene expression and protein interactions to simulating the behavior of entire biological systems. Computational biology plays a critical role in modern research, especially in genomics, proteomics, systems biology, and drug discovery. It allows scientists to analyze large datasets—such as the human genome or microbiome data—rapidly and with unprecedented accuracy, leading to breakthroughs in personalized medicine, disease modeling, and evolutionary biology. As biological data continues to grow exponentially, the importance of computational biology increases, providing researchers with the tools to extract meaningful insights, develop new therapies, and understand the underlying mechanisms of life at the molecular and systemic levels.
What Technological Advancements Are Driving Computational Biology?
The field of computational biology has seen significant advances, largely driven by technological innovations that have expanded its capacity to handle and interpret vast amounts of biological data. One of the most influential technologies is next-generation sequencing (NGS), which has drastically reduced the time and cost required to sequence DNA and RNA, generating massive datasets that computational biology tools can process to uncover genetic variations, mutations, and patterns. Coupled with advancements in high-performance computing (HPC), researchers can now analyze complex biological networks and large datasets in a fraction of the time previously required. Artificial intelligence (AI) and machine learning are also transforming computational biology, enabling predictive modeling, pattern recognition, and automated hypothesis generation in areas such as drug discovery and personalized medicine. AI algorithms can sift through massive biological datasets to predict drug-target interactions, patient responses to treatments, and even the emergence of disease outbreaks. Additionally, cloud computing has made computational biology more accessible by providing scalable resources for data storage and processing, fostering collaboration across global research teams. These advancements have greatly accelerated research, allowing for more sophisticated models of biological systems, faster drug discovery, and deeper insights into complex diseases.
How Is Computational Biology Applied Across Different Research Areas?
Computational biology is applied across numerous fields within the life sciences, playing a pivotal role in genomics, drug discovery, systems biology, and evolutionary biology. In genomics, computational tools are used to sequence and analyze entire genomes, providing insights into genetic disorders, evolution, and individual responses to drugs, which form the foundation of personalized medicine. By identifying genetic variants and predicting their impact on protein function, computational biology enables researchers to better understand the genetic basis of diseases like cancer, Alzheimer’s, and diabetes. In drug discovery, computational models simulate how drug candidates interact with biological targets, significantly reducing the time and cost required for laboratory testing. These models help predict the efficacy and safety of potential therapies before they enter clinical trials, streamlining the drug development pipeline. In systems biology, computational approaches are used to model entire biological systems—such as metabolic pathways or cellular processes—to understand how interactions between genes, proteins, and metabolites lead to complex behaviors in organisms. This holistic understanding is crucial for identifying potential therapeutic targets and for developing treatments for multifactorial diseases. Evolutionary biology also benefits from computational biology, where large-scale datasets allow researchers to trace the evolutionary history of species, understand the impact of natural selection on genomes, and predict how organisms might adapt to environmental changes. Across these diverse fields, computational biology enables scientists to make sense of biological complexity and translate data into actionable insights.
What Factors Are Driving the Growth of the Computational Biology Market?
The growth in the computational biology market is driven by several key factors, reflecting both technological advancements and evolving research needs. One of the primary drivers is the increasing volume and complexity of biological data being generated from next-generation sequencing (NGS), CRISPR gene editing, and other advanced biotechnologies. As the cost of sequencing continues to drop, more researchers and institutions are generating large datasets that require sophisticated computational tools to analyze and interpret, fueling the demand for computational biology solutions. Another important factor is the rise of personalized medicine, which relies heavily on computational models to analyze genetic information and tailor treatments to individual patients based on their unique genetic profiles. This shift towards precision medicine is creating new opportunities for computational biology in drug discovery, diagnostics, and treatment planning. Additionally, the growing use of artificial intelligence (AI) and machine learning in life sciences is accelerating the adoption of computational biology, as these technologies provide powerful tools for identifying patterns, predicting outcomes, and optimizing research strategies. The increasing integration of computational biology with bioinformatics and biotechnology industries, particularly in pharmaceutical and biotechnology companies, is also a major growth driver, as businesses seek to leverage computational tools to expedite drug discovery and reduce R&D costs. Furthermore, the need for better disease modeling, especially in light of global health challenges such as pandemics, is pushing researchers and healthcare institutions to invest in computational biology to predict disease outbreaks, model epidemiological trends, and develop new treatments more rapidly. Lastly, government and academic funding for genomics research and life sciences innovation is further propelling the growth of the computational biology market, as public and private sectors recognize its potential to revolutionize healthcare, agriculture, and environmental management. These factors collectively underscore the rapid expansion of computational biology, as it becomes an essential tool for solving some of the most pressing challenges in modern science and medicine.
SCOPE OF STUDY:The report analyzes the Computational Biology market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Service (Contract Services, In-House Services); Application (Drug Discovery & Disease Modelling, Cellular & Biological Simulation, Clinical Trials, Preclinical Drug Development, Human Body Simulation Software); End-Use (Commercial, Academics, Industrial)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
SELECT PLAYERS -
- Certara, Inc.
- Chemical Computing Group ULC
- Compugen Ltd.
- Dassault Systemes SE
- Genedata AG
- Nimbus Therapeutics
- Rosa & Co., LLC
- Schrodinger, Inc.
- Simulations Plus, Inc.
- Strand Life Sciences Pvt., Ltd.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
- Global Economic Update
- Computational Biology – Global Key Competitors Percentage Market Share in 2026 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Advancements in Genomics and Bioinformatics Expand the Addressable Market for Computational Biology Solutions
- Increasing Demand for Personalized Medicine Propels Growth of Computational Biology in Drug Discovery
- Rising Use of AI and Machine Learning in Biological Data Analysis Strengthens the Business Case for Computational Biology
- Growing Adoption of Computational Biology in Cancer Research Spurs Demand for Advanced Modeling Tools
- Innovations in High-Throughput Sequencing Throw the Spotlight on Computational Biology for Data Processing
- Surge in Synthetic Biology Research Accelerates Demand for Computational Biology in Genome Editing and Design
- Increasing Focus on Systems Biology Drives Growth of Computational Tools for Complex Biological Network Modeling
- Expansion of Biotechnology and Pharmaceutical R&D Generates Opportunities for Computational Biology in Drug Development
- Growing Use of Computational Biology in Vaccine Development Strengthens Adoption in Immunology Research
- Emerging Role of Computational Biology in Agriculture Expands Opportunities for Crop Improvement and Genetic Engineering
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Computational Biology Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
- TABLE 2: World Recent Past, Current & Future Analysis for Computational Biology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
- TABLE 3: World 8-Year Perspective for Computational Biology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2026 & 2032
- TABLE 4: World Recent Past, Current & Future Analysis for Databases Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
- TABLE 5: World 8-Year Perspective for Databases Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
- TABLE 6: World Recent Past, Current & Future Analysis for Infrastructure & Hardware Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
- TABLE 7: World 8-Year Perspective for Infrastructure & Hardware Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
- TABLE 8: World Recent Past, Current & Future Analysis for Software Platform Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
- TABLE 9: World 8-Year Perspective for Software Platform Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
- TABLE 10: World Recent Past, Current & Future Analysis for Drug Discovery & Disease Modelling Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
- TABLE 11: World 8-Year Perspective for Drug Discovery & Disease Modelling Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
- TABLE 12: World Recent Past, Current & Future Analysis for Preclinical Drug Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
- TABLE 13: World 8-Year Perspective for Preclinical Drug Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
- TABLE 14: World Recent Past, Current & Future Analysis for Clinical Trial Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
- TABLE 15: World 8-Year Perspective for Clinical Trial Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
- TABLE 16: World Recent Past, Current & Future Analysis for Computational Genomics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
- TABLE 17: World 8-Year Perspective for Computational Genomics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
- TABLE 18: World Recent Past, Current & Future Analysis for Computational Proteomics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
- TABLE 19: World 8-Year Perspective for Computational Proteomics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
- TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
- TABLE 21: World 8-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
- TABLE 22: World Recent Past, Current & Future Analysis for Academic & Research End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
- TABLE 23: World 8-Year Perspective for Academic & Research End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
- TABLE 24: World Recent Past, Current & Future Analysis for Industrial End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
- TABLE 25: World 8-Year Perspective for Industrial End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
- III. MARKET ANALYSIS
- UNITED STATES
- Computational Biology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
- TABLE 26: USA Recent Past, Current & Future Analysis for Computational Biology by Application - Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 27: USA 8-Year Perspective for Computational Biology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications for the Years 2026 & 2032
- TABLE 28: USA Recent Past, Current & Future Analysis for Computational Biology by End-Use - Academic & Research End-Use and Industrial End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 29: USA 8-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academic & Research End-Use and Industrial End-Use for the Years 2026 & 2032
- TABLE 30: USA Recent Past, Current & Future Analysis for Computational Biology by Offering - Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 31: USA 8-Year Perspective for Computational Biology by Offering - Percentage Breakdown of Value Sales for Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering for the Years 2026 & 2032
- CANADA
- TABLE 32: Canada Recent Past, Current & Future Analysis for Computational Biology by Application - Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 33: Canada 8-Year Perspective for Computational Biology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications for the Years 2026 & 2032
- TABLE 34: Canada Recent Past, Current & Future Analysis for Computational Biology by End-Use - Academic & Research End-Use and Industrial End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 35: Canada 8-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academic & Research End-Use and Industrial End-Use for the Years 2026 & 2032
- TABLE 36: Canada Recent Past, Current & Future Analysis for Computational Biology by Offering - Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 37: Canada 8-Year Perspective for Computational Biology by Offering - Percentage Breakdown of Value Sales for Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering for the Years 2026 & 2032
- JAPAN
- Computational Biology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
- TABLE 38: Japan Recent Past, Current & Future Analysis for Computational Biology by Application - Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 39: Japan 8-Year Perspective for Computational Biology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications for the Years 2026 & 2032
- TABLE 40: Japan Recent Past, Current & Future Analysis for Computational Biology by End-Use - Academic & Research End-Use and Industrial End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 41: Japan 8-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academic & Research End-Use and Industrial End-Use for the Years 2026 & 2032
- TABLE 42: Japan Recent Past, Current & Future Analysis for Computational Biology by Offering - Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 43: Japan 8-Year Perspective for Computational Biology by Offering - Percentage Breakdown of Value Sales for Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering for the Years 2026 & 2032
- CHINA
- Computational Biology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
- TABLE 44: China Recent Past, Current & Future Analysis for Computational Biology by Application - Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 45: China 8-Year Perspective for Computational Biology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications for the Years 2026 & 2032
- TABLE 46: China Recent Past, Current & Future Analysis for Computational Biology by End-Use - Academic & Research End-Use and Industrial End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 47: China 8-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academic & Research End-Use and Industrial End-Use for the Years 2026 & 2032
- TABLE 48: China Recent Past, Current & Future Analysis for Computational Biology by Offering - Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 49: China 8-Year Perspective for Computational Biology by Offering - Percentage Breakdown of Value Sales for Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering for the Years 2026 & 2032
- EUROPE
- Computational Biology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
- TABLE 50: Europe Recent Past, Current & Future Analysis for Computational Biology by Application - Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 51: Europe 8-Year Perspective for Computational Biology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications for the Years 2026 & 2032
- TABLE 52: Europe Recent Past, Current & Future Analysis for Computational Biology by End-Use - Academic & Research End-Use and Industrial End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 53: Europe 8-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academic & Research End-Use and Industrial End-Use for the Years 2026 & 2032
- TABLE 54: Europe Recent Past, Current & Future Analysis for Computational Biology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
- TABLE 55: Europe 8-Year Perspective for Computational Biology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2026 & 2032
- TABLE 56: Europe Recent Past, Current & Future Analysis for Computational Biology by Offering - Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 57: Europe 8-Year Perspective for Computational Biology by Offering - Percentage Breakdown of Value Sales for Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering for the Years 2026 & 2032
- FRANCE
- Computational Biology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
- TABLE 58: France Recent Past, Current & Future Analysis for Computational Biology by Application - Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 59: France 8-Year Perspective for Computational Biology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications for the Years 2026 & 2032
- TABLE 60: France Recent Past, Current & Future Analysis for Computational Biology by End-Use - Academic & Research End-Use and Industrial End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 61: France 8-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academic & Research End-Use and Industrial End-Use for the Years 2026 & 2032
- TABLE 62: France Recent Past, Current & Future Analysis for Computational Biology by Offering - Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 63: France 8-Year Perspective for Computational Biology by Offering - Percentage Breakdown of Value Sales for Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering for the Years 2026 & 2032
- GERMANY
- Computational Biology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
- TABLE 64: Germany Recent Past, Current & Future Analysis for Computational Biology by Application - Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 65: Germany 8-Year Perspective for Computational Biology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications for the Years 2026 & 2032
- TABLE 66: Germany Recent Past, Current & Future Analysis for Computational Biology by End-Use - Academic & Research End-Use and Industrial End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 67: Germany 8-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academic & Research End-Use and Industrial End-Use for the Years 2026 & 2032
- TABLE 68: Germany Recent Past, Current & Future Analysis for Computational Biology by Offering - Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 69: Germany 8-Year Perspective for Computational Biology by Offering - Percentage Breakdown of Value Sales for Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering for the Years 2026 & 2032
- ITALY
- TABLE 70: Italy Recent Past, Current & Future Analysis for Computational Biology by Application - Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 71: Italy 8-Year Perspective for Computational Biology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications for the Years 2026 & 2032
- TABLE 72: Italy Recent Past, Current & Future Analysis for Computational Biology by End-Use - Academic & Research End-Use and Industrial End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 73: Italy 8-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academic & Research End-Use and Industrial End-Use for the Years 2026 & 2032
- TABLE 74: Italy Recent Past, Current & Future Analysis for Computational Biology by Offering - Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 75: Italy 8-Year Perspective for Computational Biology by Offering - Percentage Breakdown of Value Sales for Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering for the Years 2026 & 2032
- UNITED KINGDOM
- Computational Biology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
- TABLE 76: UK Recent Past, Current & Future Analysis for Computational Biology by Application - Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 77: UK 8-Year Perspective for Computational Biology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications for the Years 2026 & 2032
- TABLE 78: UK Recent Past, Current & Future Analysis for Computational Biology by End-Use - Academic & Research End-Use and Industrial End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 79: UK 8-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academic & Research End-Use and Industrial End-Use for the Years 2026 & 2032
- TABLE 80: UK Recent Past, Current & Future Analysis for Computational Biology by Offering - Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 81: UK 8-Year Perspective for Computational Biology by Offering - Percentage Breakdown of Value Sales for Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering for the Years 2026 & 2032
- REST OF EUROPE
- TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Computational Biology by Application - Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 83: Rest of Europe 8-Year Perspective for Computational Biology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications for the Years 2026 & 2032
- TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Computational Biology by End-Use - Academic & Research End-Use and Industrial End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 85: Rest of Europe 8-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academic & Research End-Use and Industrial End-Use for the Years 2026 & 2032
- TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Computational Biology by Offering - Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 87: Rest of Europe 8-Year Perspective for Computational Biology by Offering - Percentage Breakdown of Value Sales for Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering for the Years 2026 & 2032
- ASIA-PACIFIC
- Computational Biology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
- TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Computational Biology by Application - Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 89: Asia-Pacific 8-Year Perspective for Computational Biology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications for the Years 2026 & 2032
- TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Computational Biology by End-Use - Academic & Research End-Use and Industrial End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 91: Asia-Pacific 8-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academic & Research End-Use and Industrial End-Use for the Years 2026 & 2032
- TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Computational Biology by Offering - Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 93: Asia-Pacific 8-Year Perspective for Computational Biology by Offering - Percentage Breakdown of Value Sales for Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering for the Years 2026 & 2032
- REST OF WORLD
- TABLE 94: Rest of World Recent Past, Current & Future Analysis for Computational Biology by Application - Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 95: Rest of World 8-Year Perspective for Computational Biology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Disease Modelling Application, Preclinical Drug Development Application, Clinical Trial Application, Computational Genomics Application, Computational Proteomics Application and Other Applications for the Years 2026 & 2032
- TABLE 96: Rest of World Recent Past, Current & Future Analysis for Computational Biology by End-Use - Academic & Research End-Use and Industrial End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 97: Rest of World 8-Year Perspective for Computational Biology by End-Use - Percentage Breakdown of Value Sales for Academic & Research End-Use and Industrial End-Use for the Years 2026 & 2032
- TABLE 98: Rest of World Recent Past, Current & Future Analysis for Computational Biology by Offering - Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
- TABLE 99: Rest of World 8-Year Perspective for Computational Biology by Offering - Percentage Breakdown of Value Sales for Databases Offering, Infrastructure & Hardware Offering and Software Platform Offering for the Years 2026 & 2032
- IV. COMPETITION
Pricing
Currency Rates


